Very much surprised that there has been little comment about Dr Alex Roher's contribution to this study. His resume is comparable to Dr Mullan's, and his 20 year focus has been on AD and PD. Interesting that he would choose to take part in a study of the mechanism of action of anatabine, since he has not had any previous involvement with it as far as I can determine.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.